Umifenovir (Arbidol) powder 25 mg/5 ml – [37 g vial]

Description

Arbidol Pharmacodynamics
Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influ-enzavirus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses – causative agents of acute respiratory viral infections (ARI) (Coronavirus (Coronavirus) associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus). By the mechanism of antiviral action it belongs to fusion inhibitors (fusion), it interacts with hemagglutinin of the virus and prevents fusion of lipid coating of the virus and cell membranes. It has a moderate immunomodulatory effect and increases resistance of the organism to viral infections. It has interferon-inducing activity: in tests on mice interferon induction was observed in 16 hours, and high titers of interferon were kept in blood up to 48 hours after injection. It stimulates cellular and humoral immune reactions: it increases the number of lymphocytes in blood, in particular the number of T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK-cells).
Therapeutic effectiveness in viral infections is manifested in reduction of duration and severity of the course of disease and its main symptoms, as well as in reduction of the frequency of development of complications due to viral infection and exacerbations of chronic bacterial diseases.
In treatment of flu or acute respiratory viral infections in adults, clinical trial showed that Arbidol® effect in adults is most expressed in acute period of disease and is expressed by reduction of terms of resolution of disease symptoms, decrease of disease severity and shortening of terms of virus elimination.
Therapy with Arbidol® results in higher rate of resolution of disease symptoms on the third day of therapy compared to placebo. In 60 hours after the therapy start, the resolution of all symptoms of laboratory confirmed influenza is more than 5 times higher than in the placebo group.
A significant effect of Arbidol® was found on the rate of elimination of influenza virus, which, in particular, was manifested by a decrease in the frequency of detection of RNA virus on the 4th day.
The drug is considered to be low-toxic (LD50 > 4 g/kg). It does not have any negative effect on the human body when administered orally in the recommended doses.

Indications
– Prevention and treatment of influenza A and B, other acute respiratory infections in children from 2 years old and adults;
– Complex therapy of acute intestinal infections of rotavirus aetiology in children from 2 years old.

Contraindications .
Hypersensitivity to umifenovir or any component of the drug.
Age under 2 years. The first trimester of pregnancy. Breast-feeding period.
Sucrose/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.

Dosage and administration

• Inside, before a meal.
  Preparation of suspension.
• Add 30 ml (or about 2/3 of the vial volume) of boiled water, cooled to room temperature, to the vial with the powder. Close the bottle with the lid, turn it over and shake thoroughly until a homogeneous suspension is obtained. Add boiled and cooled water to the volume of 100 ml (up to the mark on the bottle) and shake again. Shake the contents of the bottle thoroughly before each use until a homogeneous suspension is obtained. Measure the single dose with the attached measuring spoon.
• Single dose (depending on age):
  Age The single dose,
  ml of suspension
  (mg of Umifenovir)
  2 to 6 years old 10 ml (50 mg)
  6 to 12 years old 20 ml (100 mg)
  Over 12 years of age and adults 40 ml (200 mg)
  Dosing regimen (depending on age):
  Indication Dosing regimen
• The dosage regimen
  In children from 2 years old and adults:
  Non-specific prophylaxis during epidemics of influenza and other acute respiratory infections in a single dose
  2 times a week
  For 3 weeks.
• Non-specific prophylaxis in case of direct contact with influenza and other acute respiratory viral infections at a single dose
  1 time a day
  For 10-14 days.
  Treatment of influenza and other acute respiratory viral infections.
  4 times a day
  (every 6 hours).
  For 5 days.
• In children from 2 years old:
  Complex therapy of acute intestinal infections of rotavirus etiolo-gy in a single dose
  4 times a day
  (every 6 hours).
  Within 5 days.
• Use the drug only according to the indications, the method of administration and the doses given in the instructions.
• The drug administration starts as soon as the first symptoms of influenza and other acute respiratory infections appear, preferably within 3 days after the disease onset.
  If after using Arbidol® during three days in treatment of flu and other acute respiratory viral infections the severity of symptoms, including high temperature (38 °c and more) remains, it is necessary to see a doctor to estimate the validity of using the drug.
• During the treatment of influenza and acute respiratory infections, concomitant symptomatic therapy is possible, including antipyretic drugs, mucolytic and local vasoconstrictors.